Figure 5

From: Candesartan, an Angiotensin II AT1-Receptor Blocker and PPAR-γ Agonist, Reduces Lesion Volume and Improves Motor and Memory Function After Traumatic Brain Injury in Mice

Figure 5

Candesartan treatment improves motor and cognitive function in mice after CCI. (a) Time (seconds) that mice were able to remain on the rotarod in pre-training and at 1 and 3 days post-injury (dpi). Candesartan treatment (CD) enhanced the ability of mice to stay on the rotarod after either sham (SH) surgery or CCI mice compared with vehicle (VH)-treated mice but did not alter the ability of naive (NAI) mice to perform this test (mean±SEM, n=8–12, ***p<0.008, **p<0.005, *p<0.05) at 1 and 3 dpi. (b) MWM testing showed that after CCI injury mice treated with CD spent more time in the northwest (NW) quadrant from where the platform was removed in the probe trial, compared with mice receiving VH at 28 dpi. Thus, CD treatment led to a greater ability to learn and remember the location of a hidden platform (mean±SEM, n=5 SH-VH, n=3 SH-CD, n=7 CCI-VH, n=8 CCI-CD, *p<0.05).